老虎證券

BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

Reuters
03-06
BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

March 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:

  • ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS

  • ARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025

  • ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM

  • ARS PHARMACEUTICALS INC: IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX

Source text: ID:nGNX3b0hhs

Further company coverage: SPRY.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10